144 related articles for article (PubMed ID: 11739491)
1. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12.
Le HN; Lee NC; Tsung K; Norton JA
J Immunol; 2001 Dec; 167(12):6765-72. PubMed ID: 11739491
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
3. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
4. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
6. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
7. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
8. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population.
Karnbach C; Daws MR; Niemi EC; Nakamura MC
J Immunol; 2001 Sep; 167(5):2569-76. PubMed ID: 11509597
[TBL] [Abstract][Full Text] [Related]
9. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.
Tsung K; Meko JB; Tsung YL; Peplinski GR; Norton JA
J Immunol; 1998 Feb; 160(3):1369-77. PubMed ID: 9570556
[TBL] [Abstract][Full Text] [Related]
10. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
Kahan BD; Nomi S; Pellis NR
Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
[TBL] [Abstract][Full Text] [Related]
11. The inability of adoptive immunotherapy to eradicate tumor cells in radiation-induced chimeric mice: the possible down-regulation of intratumor immune amplification.
Evans R; Duffy TM
Int J Cancer; 1987 Feb; 39(2):226-31. PubMed ID: 2948923
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.
Vierboom MP; Bos GM; Ooms M; Offringa R; Melief CJ
Int J Cancer; 2000 Jul; 87(2):253-60. PubMed ID: 10861484
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
14. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
17. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
19. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level.
Mazzolini G; Qian C; Narvaiza I; Barajas M; Borrás-Cuesta F; Xie X; Duarte M; Melero I; Prieto J
Hum Gene Ther; 2000 Jan; 11(1):113-25. PubMed ID: 10646644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
